世界の抗体医薬の成長機会

費用対効果の高い効率的な連続製造プロセスやシングルユースバイオリアクターの活用が進み、開発から商業化までの期間も短縮されることが、世界の抗体医薬市場の開拓に拍車をかけると考えられています。癌免疫の部門が、特に標的特異性の高い抗体薬物複合体や二重特異性抗体の出現により、抗体医薬市場の主要な注目分野として位置づけられています。主要製造業者は、CDMOの能力を活用しようと努めており、今後5年間で市場の様相が一変する可能性が高いと考えられています。

本当レポートでは、世界の抗体医薬の市場を調査し、市場背景、市場への各種影響因子の分析、パイプライン、技術動向、償還シナリオ、収益の推移・予測、競合環境、収益シェア、成長機会の分析などをまとめています。

目次

戦略的必須要件

• 成長がますます困難になる理由
• Strategic Imperative 8（TM）
• 上位3つの戦略的必須要件の市場への影響
• Growth Pipeline Engine（TM）を推進する成長機会

成長機会の分析

• 分析範囲
• 分類・定義
• 技術の詳細区分の定義
• 成長促進要因
• 成長抑制要因
• 重要ポイント

成長環境

• 抗体治療：パイプラインのスナップショット
• 後期抗体医薬のパイプラインシナリオ
• 潜在的な治療分野
• バリューチェーン：主要ステークホルダー
• 主要な抗体医薬メーカー
• 地域別の主要な産業動向
• 投与経路別の主要な産業動向
• 主要な業界動向：抗体薬物複合体
• 主要な業界動向：技術の進歩
• 抗体医薬の価格分析
• 抗体医薬の価格に影響を与える要因
• 抗体医薬の償還シナリオ
• 抗体医薬の償還：地域の概要
• 抗体医薬の注目の提携・協力

収益予測

• 成長指標
• 調査手法
• 予測の前提条件
• 収益予測
• 収益予測分析
• 収益予測：技術別
• 収益予測：技術別 - ディスカッション
• 競合環境
• 収益シェア分析
• 注目の主要ADC開発者

成長機会の領域

• 成長機会1：癌免疫のための多特異性抗体の開発
• 成長機会2：ADCのさらなる開発のためのCDMOおよびプラットフォームプロバイダーとの協力
• ADCにおける主要な提携
• 成長機会3：モノクローナル抗体バイオシミラーへのアクセシビリティと適応症の拡大

The Evolution of Next-generation Immuno-oncology Therapies for Multiple Tumor Antigens is Poised to Drive Market Growth

Market growth is likely to be fueled by the growing utilization of cost-effective and efficient continuous manufacturing processes and single-use bioreactors for production, which will also reduce the time between development and commercialization. Favorable regulatory reforms in emerging Asian countries are encouraging the manufacture and introduction of monoclonal antibody-based biosimilars, aiming to reduce the cost-burden of originator antibody therapies. The tailored approach used by manufacturers to improve the targeting efficiency of drug molecules toward multiple antigens is strengthening the pipeline portfolio of SMEs in the antibodies space and accelerating the pace of antibody drug development for cancer treatment.

Immuno-oncology remains a key focus area in the antibody therapeutics market, especially due to the emergence of highly target-specific antibody-drug conjugates and bispecific antibodies. Key manufacturers are striving to reduce in-house operations to leverage the capabilities of contract development and manufacturing organizations (CDMOs) with the aim of boosting innovation in the industry, which is likely to change the face of the market over the next 5 years.

Research Scope:

This Frost & Sullivan research service offers an outlook of the global antibody therapeutics market for 2022 and beyond, highlighting emerging trends and growth opportunities. As innovation takes center stage, the market is likely to witness remarkable growth in the near future, attributable to the focus on bi- and multi-specific antibodies, which has augmented investments by emerging start-ups in this space. Moreover, adoption of the antibody drug co-development strategy by key market participants is rising; they use it to leverage technologically advanced drug discovery and development platforms, especially for non-standard antibody therapies, including antibody-drug conjugates.

Research Highlights:

• Conventional and recombinant antibody therapeutics market size, including key segments, from 2022 to 2027

• Dynamics around product innovation and the reimbursement scenario

• Regulatory reforms and technological advancements driving value chain transformation

• Current and future R&D efforts and investment outlook

• Growth opportunities that market participants can focus on in the near future

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Antibody Therapeutics Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation and Definition
• Definitions by Technology Subtype
• Growth Drivers
• Growth Restraints
• Key Takeaways

Growth Environment

• Antibody Therapeutics-Pipeline Snapshot
• Pipeline Scenario of Late-stage Antibody Therapeutics
• Potential Therapy Areas
• Value Chain-Key Stakeholders
• Key Antibody Therapeutics Manufacturers
• Key Industry Trends by Region
• Key Industry Trends by Region (continued)
• Key Industry Trends by Route of Administration
• Key Industry Trends-Antibody-Drug Conjugates
• Key Industry Trends-Technological Advancements
• Pricing Analysis of Antibody Therapeutics
• Factors Influencing the Pricing of Antibody Therapeutics
• Reimbursement Scenario for Antibody Therapeutics
• Reimbursement for Antibody Therapeutics-Regional Overview
• Notable Partnerships and Collaborations for Antibody Therapeutics
• Notable Partnerships and Collaborations for Antibody Therapeutics (continued)

Revenue Forecast

• Growth Metrics
• Research Methodology
• Forecast Assumptions
• Revenue Forecast
• Revenue Forecast Analysis
• Revenue Forecast by Technology
• Revenue Forecast by Technology Discussion
• Competitive Environment
• Revenue Share Analysis
• Key ADC Developers to Watch in 2022

Growth Opportunity Universe

• Growth Opportunity 1-Developing Multi-specific Antibodies for Immuno-oncology
• Growth Opportunity 1-Developing Multi-specific Antibodies for Immuno-oncology (continued)
• Growth Opportunity 2-Collaborating with CDMOs and Platform Providers for the Further Development of ADCs
• Growth Opportunity 2-Collaborating with CDMOs and Platform Providers for the Further Development of ADCs (continued)
• Key Alliances in ADCs
• Growth Opportunity 3-Expanding Accessibility to and Indications of Monoclonal Antibody Biosimilars
• Growth Opportunity 3-Expanding Accessibility to and Indications of Monoclonal Antibody Biosimilars (continued)
• List of Exhibits
• Legal Disclaimer